Introduction {#s1}
============

TRPC6, which encodes the protein transient receptor potential cation channel protein, is a non-selective cation channel, which is expressed in podocytes and interacts with nephrin and podocin to participate in signal transduction, cell polarization, skeletal structure stabilization, and other physiological functions between podocytes ([@B1]). In 2005, Winn identified an autosomal dominant family of focal segmental glomerulosclerosis (FSGS) with a point mutation in the TRPC6 gene on chromosome 11q ([@B2]). Since then, some new mutations of TRPC6 have been reported. It was confirmed that 24 mutations of the TRPC6 gene were involved in the pathogenesis of FSGS ([Table 1](#T1){ref-type="table"}). However, other pathological types associated with TRPC6 mutations have been less reported. Herein, we report on two children with novel TRPC6 mutations related to immune complex-mediated glomerulonephritis and minor glomerular abnormality (MGA).

###### 

Mutations in TRPC6 protein currently identified to cause kidney disease.

  **TRPC6 mutation**   **Published time**   **Effect on ion channel function**                             **Ethnicity**      **Phenotype**                 **Age at presentation (years)**   **Change in current amplitude**   **References**
  -------------------- -------------------- -------------------------------------------------------------- ------------------ ----------------------------- --------------------------------- --------------------------------- ----------------
  P112Q                2005-07              Increased current amplitude                                    Caucasian          AD FSGS                       30--40                            Yes                               ([@B2])
  N143S                2005-07              Not evaluated                                                  African American   AD FSGS                       30--40                            None identified                   ([@B1])
                       2009-11              Increased current amplitude                                    Caucasian          AD FSGS                       27--39                            Yes                               ([@B3])
  S270T                2005-07              Not evaluated                                                  Colombian          AD FSGS                       17--52                            None identified                   ([@B1])
  K874X                2005-07              Not evaluated                                                  Polish             AD FSGS                       27--57                            None identified                   ([@B1])
  R895C                2005-07              Increased current amplitude                                    Mexican            AD FSGS                       18--46                            Yes                               ([@B1])
                       2011-04              Not evaluated                                                  Caucasian          AD collapsing FSGS            21--38                            None identified                   ([@B4])
                       2017-04              Not evaluated                                                  Caucasian          AD FSGS                       30                                None identified                   ([@B5])
                       2017-08              Not evaluated                                                  Caucasian          AD FSGS                       5                                 None identified                   ([@B6])
                       2020                 Not evaluated                                                  Japanese           C1q nephropathy               3                                 None identified                   ([@B7])
  E897K                2005-07              Increased current amplitude                                    Irish and German   AD FSGS                       24--35                            Yes                               ([@B1])
  Q889K                2008-11              Increased current amplitude                                    Chinese            AD FSGS                       35--41                            Yes                               ([@B8])
                       2013                 Not evaluated                                                  Chinese            FSGS                          35--48                            None identified                   ([@B9])
  M132T                2009-11              Increased current amplitude and delayed channel inactivation   Caucasian          AD FSGS                       9--30                             Yes                               ([@B3])
                       2010-02              Not evaluated                                                  Caucasian          FSGS                          8                                 None identified                   ([@B10])
  G109S                2009-05              Probably damaging                                              Caucasian          FSGS                          21                                None identified                   ([@B11])
  N125S                2009-05              Probably damaging                                              Caucasian          sporadic FSGS                 41                                None identified                   ([@B11])
                       2011-06              Increased intracellular calcium                                Caucasian          MCD                           4                                 Yes                               ([@B12])
                       2011-06              Increased intracellular calcium                                Caucasian          IgAN with MPGN-like pattern   14                                Yes                               ([@B12])
  L780P                2009-05              Possibly damaging                                              Caucasian          sporadic FSGS                 7                                 None identified                   ([@B11])
  89fsX8               2010-02              Not evaluated                                                  Caucasian          FSGS                          7                                 None identified                   ([@B10])
  G757D                2010-02              Not evaluated                                                  Caucasian          FSGS                          1                                 None identified                   ([@B10])
  L395A                2011-04              Not evaluated                                                  Turkish            sporadic FSGS                 2.4                               None identified                   ([@B13])
  R360H                2011-05              Not evaluated                                                  Caucasian          FSGS                          34                                None identified                   ([@B14])
  H218L                2011-06              Increased intracellular calcium                                Caucasian          sporadic FSGS                 8                                 Yes                               ([@B12])
  R895L                2011-06              Increased intracellular calcium                                Caucasian          sporadic collapsing FSGS      1                                 Yes                               ([@B12])
  D873fsX878           2013                 Not evaluated                                                  Korean             MCD                           34                                None identified                   ([@B15])
  R175Q                2013-01              Increased intracellular calcium                                Dutch              AD FSGS                       27--53                            Yes                               ([@B16])
  A404V                2014-07              Not evaluated                                                  Caucasian          MN                            not mentioned                     None identified                   ([@B17])
  P15S                 2014-07              Not evaluated                                                  Caucasian          MN                            not mentioned                     None identified                   ([@B17])
  R68W                 2015                 Increased intracellular calcium                                Singaporean        FSGS                          7--17                             Yes                               ([@B18])
  R175W                2017-02              Not evaluated                                                  Chinese            FSGS                          4 months                          None identified                   ([@B19])
  D130V                2018-11              Not evaluated                                                  Iranian            FSGS                          5                                 None identified                   ([@B20])
  G162R                2018-11              Not evaluated                                                  Iranian            FSGS                          9                                 None identified                   ([@B20])
                       2020                 Not evaluated                                                  Japanese           AD FSGS                       2                                 None identified                   ([@B7])
  G109D                2020                 Not evaluated                                                  Japanese           MGA                           7                                 None identified                   ([@B7])
  G875V                2020                 Not evaluated                                                  Japanese           AD FSGS                       14                                None identified                   ([@B7])
  H145R                2020                 Not evaluated                                                  Japanese           AD FSGS                       7                                 None identified                   ([@B7])

*MCD, minimal change disease; IgAN with MPGN-like pattern, IgA nephropathy with a membranoproliferative glomerulonephritis (MPGN)-like pattern; AD, autosomal dominant; FSGS, focal segmental glomerulosclerosis; MGA, minor glomerular abnormality; MN, membranous nephropathy*.

Case Presentation {#s2}
=================

Case 1
------

A 10-year-old Chinese girl presented at the age of 9 years with steroid-resistant nephrotic syndrome (SRNS). The patient tested serologically negative for hepatitis B virus, human immunodeficiency virus, antinuclear antibodies (ANA) spectrum, and cytoplasmic and perinuclear antineutrophil cytoplasmic autoantibodies. She had periorbital edema and all other physical examinations were normal. She had a normal cardiac exam, normal nails and patellae, and no rashes or arthritis. Her percutaneous kidney biopsy demonstrated 6/26 showing as globally obsolete, 3/26 showing segmental sclerosis, and 1 having a cellular crescent. Mesangial cellularity was mildly increased, and tubules showed a patchy atrophy. Immunofluorescence staining showed that 1+ for C3 and C1q, IgG and IgM were 2+. Electron microscopy revealed that the distribution of medium electron density was observed in the mesangial region and subendothelial basement membrane. No electron density was found in the epithelium of the glomerular basement membrane. The podocyte processes were widely fused ([Figure 2](#F2){ref-type="fig"}). Her treatment included atorvastatin 10 mg daily, and furosemide as needed, titrated to symptoms. Tacrolimus and cyclophosphamide had been added to steroids at different times, without success in achieving remission. No members of the family (parents and a sister) were clinically affected. To identify the pathogeny, the child and her family underwent the Whole Exome sequencing. High-throughput sequencing was performed with an Illumina NovaSeq 6000 series sequencer, and not less than 99% of the target sequence was sequenced. The detected mutations were checked in various databases (e.g., dbSNP, ExAC, ESP, OMIM, HGMD, ClinVar, etc.). It showed that a new missense change (c.329A\>G) was identified in exon 2 causing an asparagine-to-serine substitution(N110S) within the first ankyrin repeat of the TRPC6 protein ([Figure 1](#F1){ref-type="fig"}). At the onset of 5 months, the child developed chronic renal insufficiency and began hemodialysis and peritoneal dialysis.

![Genetic testing of two novel TRPC6 mutations. The arrow shows the position where base substitution results in changes in amino acids.](fped-08-00269-g0001){#F1}

![Renal pathological presentation of two proband. **(A,G)** for light microscopy (PAS×400); **(B--E,H,I)** for immunofluorescence; **(F)** for electron microscope. The figure of Case 2 is for subsequent biopsy.](fped-08-00269-g0002){#F2}

Case 2
------

A 7-year-old Chinese boy presented 2 days after the onset of eyelid swelling and tonsillitis. Urine dipstick tested 2+ positive for protein with no blood and 24-h protein excretion was 0.88 g. Initial serum concentrations were normal except for a slightly low albumin 3.3 g/dl and a slightly high total cholesterol 238 mg/dl. Other laboratory results showed that ANA, complement, antistreptolysin O, and serum creatinine were normal, with an initial biopsy showing IgA nephropathy (IgAN) (Lee II, M1E1S0T0). He was not edematous and did not have hypertension. He had normal nails and patellae, a normal cardiac exam, and no rashes or arthritis. His medications included losartan potassium 50 mg daily and fosinopril 10 mg daily. Cyclosporine A, mycophenolate mofetil had been added to steroids at different times, without success in achieving remission. At age 11, a subsequent biopsy was performed. Light microscopy demonstrated 1 out of 14 segmental sclerotic glomeruli with no other abnormalities. Immunofluorescence microscopy tested slightly positive for IgA and IgM. Staining for IgG, C3, and C1q was negative ([Figure 2](#F2){ref-type="fig"}). Electron microscopy showed no glomerulus. The histopathologic diagnosis was MGA. He had no family history of kidney disease. Next, the Whole Exome sequencing was performed on the patient and his parents (case 2 used the same detection method as case 1). It showed that a new missense change (c.335C\>G) was identified in exon 2 causing a proline-to-arginine substitution (P112R) within the first ankyrin repeat of the TRPC6 protein ([Figure 1](#F1){ref-type="fig"}). He had been taking angiotensin-converting enzyme inhibitor (ACEI) as his main treatment. Current serum creatinine was 56 μmol/L, and 24-h urine showed proteinuria 1 g/day.

Discussion {#s3}
==========

TRPC6 interacts with nephrin and podocin and is an important component of the podocyte slit diaphragm ([@B3]). Mutations in genes encoding the podocyte structural proteins lead to the development of proteinuria, bringing about progressive kidney failure. To date, a total of 28 novel TRPC6 mutations have been associated with FSGS, SRNS, and proteinuria ([Table 1](#T1){ref-type="table"}). Here we first identified two novel TRPC6 mutations (N110S, P112R) that manifest as diverse types of renal pathology with early-onset, multidrug resistance, and different clinical outcomes.

Winn identified an autosomal dominant family of FSGS with a point mutation in the gene TRPC6 ([@B2]). As shown in [Table 1](#T1){ref-type="table"}, we found that the incidence of TRPC6 mutation was more familial and less sporadic. The pathological type of these two children was not FSGS and the parents were not clinically affected. But the two children were resistant to immunosuppressants, which we suspected may be caused by gene spontaneous mutations. As a result, the two children tested negative for NPHS2, NPHS1, WT1, ACTN4, COL4A5, and CD2AP genes but positive for TRPC6. Their parents\' genetic testing was normal. It shows the importance of environmental or other factors for mutations.

Several autoimmune diseases sporadically cause immune-complex deposition nephropathy. Circulating immune complexes because of autoimmune disease have been assumed to activate the classical complement pathway, which leads to glomerular injury ([@B21]). In case 1, the girl\'s response to treatment and laboratory tests would suggest that it was a non-immune-complex deposition disease. Previous studies have reported cases of IgAN and C1q nephropathy associated with TRPC6 mutations ([@B7], [@B22]), but there is no further explanation for the deposition of immune complexes in the kidney. It has been reported that several candidate genes relating to IgAN are involved in cytokine pathways, immunoregulation, and glycosylation ([@B23], [@B24]). Cox et al. identified 23 genes with candidate pathogenic variants functionally related to a large network of immune-related pathways. They speculated that the IgAN disease status may be affected by a series of mutations that affect immune-related networks ([@B25]). Milillo et al. identified the SPRY2 gene related to IgAN, which is part of the MAPK/ERK pathway ([@B26]). So, we hypothesized that variants in some pathways caused by TRPC6 mutations are risk factors for the development of immune-complex deposition nephropathy.

According to earlier studies, it has been identified that heterozygous mutations of TRPC6 cause late-onset autosomal-dominant FSGS. Heeringa et al. first reported that an M132T mutation in the TRPC6 gene can lead to early-onset FSGS in 2009 ([@B3]). Later, more and more TRPC6 mutations associated with kidney disease have been reported in children. The onset-age of the two children we reported are 7 and 9 years. Heeringa et al. believed that both a direct increase in calcium influx and an impaired channel inactivation may result in a more severe or earlier disease onset ([@B3]). It is shown in animal experiments that transient overexpression of wild-type TRPC6 in murine glomeruli causes rapid onset proteinuria ([@B27]).

The PolyPhen program predicted the TRPC6P112R(c.335C\>G) mutation in case 2 to be "probably damaging" and the SIFT program anticipated this mutation to be "Deleterious" ([Table 2](#T2){ref-type="table"}). The mutation was not found in any public database of SNP. Winn indicated that Pro112 is highly conserved in TRPC protein homologs from multiple species and the peak intracellular concentrations were considerably higher in cells expressing TRPC6P112Q(c.335C\>A) as compared with WT controls ([@B2]). The mutation in case 2 is also in Pro112, but it causes a proline-to-arginine substitution. We speculated that P112R may increase the current amplitude. The clinical manifestations and pathological type caused by P112R in our report are less severe than P112Q. The mechanism needs to be further explored. Additionally, other genetic and/or environmental factors may have an important impact on disease expressivity and penetrance. Two renal biopsies of case 2 had different outcomes, possibly because of immunofluorescence trapping. Nagano et al. found that 62% were FSGS and 28% were MGA in the histopathological diagnosis of 230 Japanese patients with proteinuria ([@B7]). MGA is a common pathological type of proteinuria, but only 1 case of MGA with normal renal function related to TRPC6 has been reported. MGA associated with TRPC6 mutation may progress slowly.

###### 

Basic characteristics and clinical manifestations of 2 children.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Patient number**   **Age (Years)**   **Biopsy**                                            **Phenotype**   **Age at diagnosis (Years)**   **Response to drugs (Steroids/CNI)**   **ESRD (Yes/No)/Years**   **Mutation**       **Protein change**   **The PolyPhen program**   **The SIFT program**   **Protein domain**
  -------------------- ----------------- ----------------------------------------------------- --------------- ------------------------------ -------------------------------------- ------------------------- ------------------ -------------------- -------------------------- ---------------------- --------------------
  1                    10                Immune complex-mediated glomerulonephritis            SRNS            9                              No/No                                  Yes/9                     c.329(exon2)A\>G   p\. N110S            Probably\                  Deleterious            ANK1
                                                                                                                                                                                                                                                       Damaging                                          

  2                    11                1\. IgA nephropathy 2. minor glomerular abnormality   Proteinuria     7                              No/No                                  No                        c.335(exon2)C\>G   p\. P112R            Probably\                  Deleterious            ANK1
                                                                                                                                                                                                                                                       Damaging                                          
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*SRNS, steroid-resistant nephrotic syndrome; CNI, calcineurin inhibitor; ESRD, End-Stage Renal Disease; ANK1, Ankyrin Repeat 1;1 for initial biopsy; 2 for subsequent biopsy*.

The PolyPhen program predicted the TRPC6N110S(c.329A\>G) mutation in case 1 to be "probably damaging" and the SIFT program anticipated this mutation to be "Deleterious" ([Table 2](#T2){ref-type="table"}). The N110S mutation, which was not found in any public database of SNP, is located very close to P112Q, within the same ankyrin repeat. Considering their close location, we speculated that the channel kinetics of both mutants would be similar. The girl in case 1 entered end-stage renal disease (ESRD) only 5 months after the onset of the disease. One patient with IgAN associated with TRPC6 mutation had normal renal function ([@B12]), while another patient with C1q nephropathy had developed ESRD in the previous report ([@B7]). They have different rates of disease progression, and IgAN may progress more slowly. As it was a novel mutation that had not been previously reported on, and because we did not enter the molecular level to learn about the mechanism, the possible explanation we can offer is that the children may have proteinuria at an early stage, but it is not detected in time.

The girl in case 1 presented with SRNS and the boy in case 2 presented with proteinuria. After the failure of steroid therapy, they added immunosuppressants to relieve proteinuria. But it still did not work. A German study showed that 81% of patients with genetic SRNS did not respond to calcineurin inhibitor (CNI)---cyclosporin A ([@B28]). There are 28 TRPC6 mutations shown in [Table 1](#T1){ref-type="table"}; eleven (P112Q, N143S, R895C, E897K, Q889K, M132T, N125S, H218L, R895L, R175Q, R68W mutation) were gain-of-function mutations that resulted in increasing calcium channel activity ([@B1]--[@B3], [@B8], [@B12], [@B16], [@B18]). CNIs may affect the CaN-NFAT signaling pathway, which may promote cell apoptosis and destroy the podocyte actin cytoskeleton, thereby improving proteinuria ([@B29]). However, two of our patients were resistant to CNI. To avoid the side effects of immunosuppressants, they have stopped using the drugs. At present, the treatment goal in both patients is to protect kidney function, delay the progression of renal decline, and promote symptomatic management. Currently, the girl in case 1 receives regular peritoneal dialysis, while the boy in case 2 only takes ACEI orally.

Herein, we reported two new mutations in the TRCP6 gene that are related to different types of renal pathology, rather than FSGS as previously reported in the literature. But their diseases progress at different rates. Even though the PolyPhen and the SIFT program are very useful for predicting probable mutations, to date the functional assay is the definitive step to determine if a variant is a mutation. The lack of animal model experiments is a limitation of our research. We hypothesized that mutations in certain pathways caused by TRPC6 mutations may be responsible for the development of immune-complex deposition nephropathy in case 1. However, the exact mechanism of this disease needs to be confirmed by further experiments.

Conclusions {#s4}
===========

Two novel TRPC6 mutations were associated with atypical phenotype---immune complex-mediated glomerulonephritis and MGA. Their rates of disease progression are different. Genetic testing is helpful to identify the etiology and avoid the side effects brought on by immunosuppressants.
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